GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)
- Conditions
- Primary Sclerosing Cholangitis (PSC)
- Interventions
- Biological: SimtuzumabBiological: Placebo
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 235
- Registration Number
- NCT01672853
- Locations
- 🇺🇸
University of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸Southern California Liver Center, Chula Vista, California, United States
🇺🇸Southern California Liver Centers, Coronado, California, United States
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 51
- Registration Number
- NCT01671787
- Locations
- 🇬🇧
Institute of Liver Studies, King's College Hospital, London, United Kingdom
🇬🇧Grahame Hayton Unit, London, United Kingdom
🇦🇺Alfred Hospital, Melbourne, Victoria, Australia
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 224
- Registration Number
- NCT01667731
Phase I Study of Milatuzumab for Graft Versus Host Disease
- Conditions
- GVHD (Acute or Chronic)Multiple Myeloma (MM)Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)Myelodysplastic SyndromeNon-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)Chronic Myelogenous Leukemia (CML)
- Interventions
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 12
- Registration Number
- NCT01663766
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01659047
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 261
- Registration Number
- NCT01659021
- Locations
- 🇺🇸
Saint Mary's Regional Cancer Center, Grand Junction, Colorado, United States
🇺🇸Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸City of Hope, Duarte, California, United States
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL
- Conditions
- Non Hodgkins LymphomaChronic Lymphocytic Leukaemia
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT01659255
- Locations
- 🇫🇷
CHU St Eloi, Montpellier, France
🇫🇷CHRU - Hopital Claude HURIEZ, Lille, France
🇫🇷Centre hospitalier Lyon Sud, Lyon, France
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: TDF Placebo
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT01651403
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇮🇳SMS Medical College and Hospital, Jaipur, Rajasthan, India
🇷🇴Grigore Alexandrescu Emergency Clinical Hospital for Children, Bucharest, Romania
Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 328
- Registration Number
- NCT01641640
- Locations
- 🇺🇸
Peter J. Ruane, MD, Inc., Los Angeles, California, United States
🇺🇸Borland-Groover Clinic Baptist, Jacksonville, Florida, United States
🇺🇸Infectious Disease Specialist of Atlanta, Decatur, Georgia, United States
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 107
- Registration Number
- NCT01641822
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States